KM Research Hub
← 返回结果库查看论文详情PubMed ↗
READ-ONLY DIGITIZATION RESULT

Prognostic relation of body mass index on extended aromatase inhibition treatment in postmenopausal patients with estrogen receptor positive breast cancer: A retrospective analysis of the SOLE trial.

Eur J Cancer · 2025-Jun-03 · PMID 40286474

Panel A_5质量警告待 EXE 对齐验证

Incidence

Fig. 3 Prognostic association of categorical BMI with BCFI. ( A) Unadjusted non-parametrical estimates of CCI of BC recurrences conditioned on prior endocrine treatment, treatment arm and BMI category. (B) Forest plot of the estimated risk ratios of BC recurrences between patients with normal weight and overweight (blue) and between patients with normal weight and obesity (purple) adjusted for tumor size, grade, histology, number of positive lymph nodes, and age. Patients with normal weight are the reference category. (C) Estimated risk ratios for the other covariates in the multivariable model: tumor grade, tumor size, histology, and number of positive lymph nodes. (D) Plot of the non-linear effect of age, modelled with a restricted cubic spline. The risk ratios (solid line) are computed with respect to a subject of 53 years of age as the reference. Dashed lines represent the 95 % CIs. Abbreviations: BC: breast cancer; BCFI: breast cancer free interval; BMI: body mass index; CCI: crude cumulative incidence; CIs: confidence intervals.

算法:legacy-0.5.0引擎:enhanced-linux
质量评分0.64
质量通过否
预期曲线3
实际曲线2
X 范围-
Y 范围-

曲线数据

网页最多预览 200 行,完整数据请下载 CSV 或 JSON。

当前面板没有可预览的 `curves_mapped.csv` 数据。
历史版本(1)

重跑只新增版本,不覆盖旧结果;正式可用状态仅授予通过 EXE 基准或人工复核的版本。

版本状态验证曲线时间
legacy-0.5.0quality_warning待验证22026-07-23T17:40:51+00:00